Name | Ecopipam |
Description | Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1/D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam demonstrates more than 40-fold selectivity over D2, D4, 5-HT, and α2a receptors (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). It is used in research on schizophrenia and obesity. |
In vitro | Ecopipam (2 μM) completely abolishes the proconvulsive effect of Dopamine (10 μM) in isolated corticohippocampal formation[2]. |
In vivo | Ecopipam (0.003-0.3 mg/kg; a single s.c.) abolishes nicotine-induced enhancement of a sensory reinforcer in adult rats[3]. Ecopipam (10 mg/kg, oral administration) antagonizes apomorphine-induced stereotypy in rats[4]. Ecopipam (5 and 10 μM, perfusion, 1 μL/min) reversibly and dose-dependently decreases acetylcholine release in the rat striatum[5]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 60 mg/mL (191.19 mM)
|
Keywords | Ecopipam |
Inhibitors Related | CLOZAPINE N-OXIDE | Octopamine hydrochloride | Oxolinic acid |
Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |